Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
作者： Shai Ashkenazi , Justen H. Passwell , Efrat Harlev , Dan Miron , Ron Dagan
DOI: 10.1086/314759
关键词:
摘要: O-specific polysaccharide conjugates of shigellae were safe and immunogenic in young adults, a Shigella sonnei conjugate conferred protection [1-3]. Shigellosis is primarily disease children; therefore, the safety immunogenicity S. flexneri 2a studied 4- to 7-year-old children. Local systemic reactions minimal. The first injection both elicited significant rises geometric mean levels serum IgG only homologous lipopolysaccharide (LPS) (S. sonnei, 0.32-8.25 ELISA units [EU]; 2a, 1.15-20.5 EU; P <.0001). Revaccination at 6 weeks induced booster response LPS (20.5-30.5 EU, =.003). Six months later, anti-LPS for groups higher than prevaccination (P<.0001). Similar, but lesser, observed IgM IgA anti-LPS. investigational children merit evaluation their efficacy.
oup.com
core.ac.uk
paperity.org
oxfordjournals.org
jstor.org 参考文章(12)
Kenneth H. Brown, Robert E. Black, Stan Becker, Effects of Diarrhea Associated with Specific Enteropathogens on the Growth of Children in Rural Bangladesh Pediatrics. ,vol. 73, pp. 799- 805 ,(1984)
Justen H. Passwell, Serem Freier, Avner Goren, Lethal toxic encephalopathy due to childhood shigellosis in a developed country. Pediatrics. ,vol. 89, pp. 1189- 1193 ,(1992)
D N Taylor, A C Trofa, J Sadoff, C Chu, D Bryla, J Shiloach, D Cohen, S Ashkenazi, Y Lerman, W Egan, Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infection and Immunity. ,vol. 61, pp. 3678- 3687 ,(1993) , 10.1128/IAI.61.9.3678-3687.1993
D Cohen, S Ashkenazi, M Green, Y Lerman, R Slepon, G Robin, N Orr, D N Taylor, J C Sadoff, C Chu, J Shiloach, R Schneerson, J B Robbins, Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infection and Immunity. ,vol. 64, pp. 4074- 4077 ,(1996) , 10.1128/IAI.64.10.4074-4077.1996
J. B. Robbins, C. Chu, R. Schneerson, Hypothesis for Vaccine Development: Protective Immunity to Enteric Diseases Caused by Nontyphoidal Salmonellae and Shigellae May Be Conferred by Serum IgG Antibodies to the O-Specific Polysaccharide of Their Lipopolysaccharides Clinical Infectious Diseases. ,vol. 15, pp. 346- 361 ,(1992) , 10.1093/CLINIDS/15.2.346
JUSTEN H. PASSWELL, SEREM FREIER, RUTH SHOR, NAHID FARZAM, COLIN BLOCK, MICHAEL LISON, EYAL SHIFF, SHAI ASHKENAZI, Shigella lipopolysaccharide antibodies in pediatric populations Pediatric Infectious Disease Journal. ,vol. 14, pp. 859- 865 ,(1995) , 10.1097/00006454-199510000-00008
S. Ashkenazi, M. May-Zahav, G. Dinari, U. Gabbay, R. Zilberberg, Z. Samra, Recent Trends in the Epidemiology of Shigella Species in Israel Clinical Infectious Diseases. ,vol. 17, pp. 897- 899 ,(1993) , 10.1093/CLINIDS/17.5.897
J. B. Robbins, R. Schneerson, Polysaccharide-protein conjugates: a new generation of vaccines. The Journal of Infectious Diseases. ,vol. 161, pp. 821- 832 ,(1990) , 10.1093/INFDIS/161.5.821
S Ashkenazi, M May-Zahav, J Sulkes, R Zilberberg, Z Samra, Increasing antimicrobial resistance of Shigella isolates in Israel during the period 1984 to 1992. Antimicrobial Agents and Chemotherapy. ,vol. 39, pp. 819- 823 ,(1995) , 10.1128/AAC.39.4.819
Dani Cohen, Shai Ashkenazi, Manfred S Green, Michael Gdalevich, Guy Robin, Raphael Slepon, Miri Yavzori, Nadav Orr, Colin Block, Isaac Ashkenazi, Joshua Shemer, David N Taylor, Thomas L Hale, Jerald C Sadoff, Danka Pavliakova, Rachel Schneerson, John B Robbins, Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults The Lancet. ,vol. 349, pp. 155- 159 ,(1997) , 10.1016/S0140-6736(96)06255-1